Drugs / Ripasudil
Ripasudil
also known as
Glanatec · K-115 · K-115-R · K-321 · RIPASUDIL HYDROCHLORIDE DIHYDRATE · Ripasudil hydrochloride hydrate
Trials 11 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04620135 Comparator | Nov 2020 → Jul 2021 | ocular hypertension, open-angle glaucoma | Aerie Pharmaceuticals | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03249337 Comparator | Dec 2017 → Dec 2021 overdue | Fuchs' endothelial dystrophy | Marian Macsai, MD | Recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ripasudil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05528172 ↗ |
| Known as | Glanatec | “Other Name: Glanatec®” NCT04620135 ↗ |
| Known as | K-115 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3426621 ↗ |
| Known as | K-115-R | ChEMBL registry synonym — accepted as the source's own label CHEMBL3426621 ↗ |
| Known as | K-321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04250207 ↗ |
| Known as | RIPASUDIL HYDROCHLORIDE DIHYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3426621 ↗ |
| Known as | Ripasudil hydrochloride hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3426621 ↗ |
| Action | Inhibit | “a potent ROCK inhibitor” NCT03813056 ↗ |
| Modality | Small molecule | — CHEMBL3426621 ↗ |
| Route | Topical | “Glanatec eye drops will be administered 6x per day for 2-4 weeks” NCT03813056 ↗ |